Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Objectives: We sought to describe the responses of patients to clopidogrel using ex vivo
measures of platelet aggregation and activation in a large, heterogeneous population …

Background: The degree of antiplatelet response to clopidogrel has been associated with
clinical outcomes. Studies have investigated whether adjustment of antiplatelet therapies …

Antiplatelet drugs represent the basis of treatment for car-diovascular atherothrombotic
disease processes. Clopidogrel selectively inhibits the platelet adenosine diphosphate …

Platelet reactivity to agonists and subsequent activation are important factors that affect the
development of atherothrombosis and resultant ischemic events. Pharmacologic …

Oral antiplatelet therapy with clopidogrel and aspirin is an important and widely prescribed
strategy to prevent ischemic events in patients with cardiovascular diseases. However, the …

Antiplatelet therapy is the mainstay of treatment for patients with cardiovascular disease.
However, some patients experience adverse cardiac events despite treatment with single-or …

Clopidogrel is an antithrombotic prodrug, whose active metabolite inhibits platelet function
by irreversibly binding to the platelet receptor for adenosine diphosphate, P2Y 12. Wide inter …

The existence of poor biological response to clopidogrel has been shown in some patients.
Despite the increasing number of studies, this phenomenon remains difficult to quantify. We …

We performed this meta-analysis to update the clinical evidences on the relation between
clopidogrel non-responsiveness and clinical outcomes in patients with coronary artery …